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Mast cells that accumulate cholesterol 
precursors in their membranes tend to 
overreact, according to Kovarova and 
colleagues on page 1161. This mast cell 
hyperresponsiveness might help explain 
why patients with a genetic disease 
known as Smith-Lemli-Opitz syndrome 
(SLOS) are prone to food allergies.
Patients with SLOS have abnormally 
low levels of circulating cholesterol—
and a corresponding abundance of the 
cholesterol precursor 7-dehydrocholes-
terol (DHC)—due to defects in the gene 
that encodes the DHC-reducing en-
zyme (DHCR7). This cholesterol defi-
ciency causes a bevy of developmental 
defects, consistent with the known re-
quirement for cholesterol during embry-
onic development.
But the allergic manifestations of 
SLOS are poorly understood. Kovarova 
and colleagues suspected that mast cells—
the principle allergy-triggering cell 
type—might be involved, as mast cells 
rely on the proper distribution of cho-
lesterol-rich lipid rafts in their mem-
branes for appropriate activation and 
deactivation.
Their hunch was right. Mast cells 
from  Dhcr7-deficient mice were hy-
peractive compared with wild-type 
cells, as measured by increased degran-
ulation and proinflammatory cytokine 
production upon activation. But to 
their surprise, the deficient cells had 
normal numbers of lipid rafts—al-
though the abundance of DHC and 
paucity of cholesterol made the rafts 
less stable than normal.
The destabilized rafts contained 
fewer molecules of the kinase Lyn, lead-
ing to a decrease in the Lyn-dependent 
activation of Csk-binding protein, a 
negative regulator of the degranulation-
stimulating kinase Fyn. Depleting wild-
type cells of cholesterol had the same 
activation-enhancing effect, which was 
reversed when cholesterol was added 
back. But adding cholesterol to the 
Dhcr7-deficient cells had minimal effect, 
suggesting that the activation defect was 
caused by the accumulation of DHC, 
rather than the depletion of cholesterol.
These results suggest that patients 
with other diseases involving defects in 
cholesterol biosynthesis might be more 
prone to allergies—a possibility that re-
mains to be tested. 
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Degranulation is enhanced in mast cells lacking 
the enzyme that reduces 7-dehydrocholesterol 
(DHCR KO).
MIF magnifies malarial anemia
A study on page 1185 shows that the immune system’s attempt to 
fight off malaria-causing parasites triggers severe anemia, a lethal 
complication of the disease. Parasite-induced synthesis of the cytokine 
MIF (migration inhibitory factor), say McDevitt and colleagues, 
decreases the production of red blood cells (RBCs) from the bone marrow.
Parasites of the Plasmodium genus use host RBCs as 
multiplication factories, rupturing the cells as progeny parasites 
exit. Plasmodium infection also hampers the production of new 
RBCs from the bone marrow, an effect this group recently 
attributed to MIF, which is produced by macrophages that ingest 
infected RBCs. MIF helps activate T cells and is required to combat 
other infectious microbes including Salmonella and Leishmania.
But in malaria, MIF works against the host (although it probably 
also has benefits). In their new study, McDevitt et al. confirm MIF 
as the culprit of malarial anemia by showing that parasite-infected 
mice that lack MIF were less anemic and survived longer than wild-
type mice. In vitro, the cytokine both suppressed the differentiation of RBCs from progenitor cells and 
decreased their hemoglobin content, possibly as a result of disrupted ERK–MAPK signaling in these cells.
Monocytes from humans carrying known “high producer” MIF gene polymorphisms secreted more MIF 
in response to the malarial pigment hemozoin than did those from individuals without this allele. And this 
group recently found a high prevalence of the low producer genotype among malaria-infected people in 
endemic regions of Africa, perhaps the result of an evolutionary survival advantage of keeping MIF levels low.
Population studies are now underway to determine whether MIF levels influence susceptibility to or severity of 
malaria in humans. In the meantime, synthetic inhibitors of MIF—currently in clinical development—might provide an 
effective alternative to the costly (and risky) blood transfusions currently used to treat malarial anemia. 
The cytokine MIF, produced by macrophages in response to 
malarial hemozoin (black), triggers anemia in the infected host.